118.08
2.79 (2.42%)
| Previous Close | 115.29 |
| Open | 115.02 |
| Volume | 645,569 |
| Avg. Volume (3M) | 1,718,144 |
| Market Cap | 17,283,960,832 |
| Price / Earnings (TTM) | 10.56 |
| Price / Earnings (Forward) | 7.82 |
| Price / Sales | 1.81 |
| Price / Book | 1.05 |
| 52 Weeks Range | |
| Earnings Date | 1 May 2025 |
| Profit Margin | 16.87% |
| Operating Margin (TTM) | 21.51% |
| Diluted EPS (TTM) | 11.18 |
| Quarterly Revenue Growth (YOY) | 2.90% |
| Quarterly Earnings Growth (YOY) | 6.80% |
| Total Debt/Equity (MRQ) | 40.18% |
| Current Ratio (MRQ) | 1.35 |
| Operating Cash Flow (TTM) | 2.88 B |
| Levered Free Cash Flow (TTM) | 3.27 B |
| Return on Assets (TTM) | 5.29% |
| Return on Equity (TTM) | 10.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bearish | Bullish |
| Drug Manufacturers - General (Global) | Bearish | Bullish | |
| Stock | Biogen Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -4.0 |
| Average | 0.13 |
|
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Mid Value |
| % Held by Insiders | 0.21% |
| % Held by Institutions | 94.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 265.00 (Canaccord Genuity, 124.42%) | Buy |
| Median | 197.00 (66.84%) | |
| Low | 115.00 (Piper Sandler, -2.61%) | Hold |
| Average | 185.64 (57.22%) | |
| Total | 6 Buy, 5 Hold | |
| Avg. Price @ Call | 129.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 29 Apr 2025 | 115.00 (-2.61%) | Hold | 120.17 |
| 18 Feb 2025 | 135.00 (14.33%) | Hold | 136.57 | |
| Truist Securities | 29 Apr 2025 | 199.00 (68.53%) | Buy | 120.17 |
| 13 Feb 2025 | 210.00 (77.85%) | Buy | 138.45 | |
| Goldman Sachs | 23 Apr 2025 | 197.00 (66.84%) | Buy | 118.17 |
| 13 Feb 2025 | 245.00 (107.49%) | Buy | 138.45 | |
| RBC Capital | 22 Apr 2025 | 225.00 (90.55%) | Buy | 118.89 |
| 13 Feb 2025 | 225.00 (90.55%) | Buy | 138.45 | |
| Morgan Stanley | 09 Apr 2025 | 152.00 (28.73%) | Hold | 120.49 |
| 13 Feb 2025 | 157.00 (32.96%) | Hold | 138.45 | |
| BMO Capital | 13 Feb 2025 | 139.00 (17.72%) | Hold | 138.45 |
| Canaccord Genuity | 13 Feb 2025 | 265.00 (124.42%) | Buy | 138.45 |
| Citigroup | 13 Feb 2025 | 145.00 (22.80%) | Hold | 138.45 |
| HC Wainwright & Co. | 13 Feb 2025 | 241.00 (104.10%) | Buy | 138.45 |
| Scotiabank | 13 Feb 2025 | 224.00 (89.70%) | Buy | 138.45 |
| Wells Fargo | 13 Feb 2025 | 140.00 (18.56%) | Hold | 138.45 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |